The advent of cancer immunotherapies, particularly immune checkpoint inhibitors (ICIs), has ushered in a new era of treatment, but it has simultaneously introduced unprecedented complexity for Companion Diagnostics (CDx). While the first wave of ICI CDx focused primarily on the immunohistochemical (IHC) detection of Programmed Death-Ligand 1 (PD-L1) protein expression on tumor cells or immune cells, it quickly became clear that PD-L1 alone is an imperfect predictive biomarker. Its expression is dynamic, heterogeneous, and the multiple, non-interchangeable assays used have caused widespread clinical confusion. This realization has driven the market toward the co-development and validation of second-generation predictive biomarkers that offer a more comprehensive view of the tumor's microenvironment and a patient’s likely response to ICI therapy.

Key emerging biomarkers, which are rapidly becoming the focus of the Companion Diagnostics for Oncology Market Segment, include Tumor Mutational Burden (TMB) and Microsatellite Instability (MSI)/Mismatch Repair (MMR) deficiency. TMB—a measure of the total number of mutations in a tumor—is tested via large-panel NGS-based CDx and has been approved for pan-cancer indications, demonstrating its power beyond single-site markers. Similarly, MSI/MMR status, also a genomic signature, predicts response to specific ICIs across multiple tumor types. The trend is moving toward a "multi-biomarker" diagnostic approach, where treatment decisions are guided by a weighted combination of PD-L1 status, TMB, MSI, and potentially other factors like interferon-gamma signatures. This shift is fueling fierce competition among diagnostic companies to develop proprietary, validated, and regulatory-approved multiplex panels that can accurately predict ICI response, confirming the deep and ongoing influence of immunotherapy on the CDx market’s growth and innovation trajectory.